{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-25-000048","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.607410+00:00","generated_at":"2026-05-17T17:11:07.062121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%","bullets":["Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).","Adjusted non-GAAP net income $40.9M ($0.85 diluted EPS) vs $48.7M ($0.94) YoY.","BAQSIMI sales increased 21% YoY, cited as key revenue driver.","Announced multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga HQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-25-000048","json":"https://secwatch.observer/filing/0001297184-25-000048.json","markdown":"https://secwatch.observer/filing/0001297184-25-000048.md","text":"https://secwatch.observer/filing/0001297184-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/0001297184-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/amph-20250807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:11:07.062121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}